Navigation path


New Approaches to Target Tuberculosis
Framework programme:
Contract/Grant agreement number:
EC contribution:
2,900,000 €
36 months
Funding scheme:
Collaborative Project (SICA)
Starting date:
Project Web site:

Keywords: Mycobacterium tuberculosis, new target inhibitors, latent infection


The increasing emergence of multidrug and extensively drug resistant strains of Mycobacterium tuberculosis, the last one being virtually untreatable, urgently demands novel drugs for tuberculosis (TB).

TB can be treated by chemotherapy. Normally, combinations of three to four drugs of first order are given over a period of four to six months. The protracted course of treatment and the side effects lead to a high proportion of non-compliance patients. This and other reasons have led to the increasing emergence of multidrug-resistant (MDR) strains which need inclusion of second-order drugs into the treatment scheme.

More recently there has been an increasing occurrence of extensively drug resistant (XDR) TB strains, so-called XDR TB; this has been recorded in 38 nations so far and is virtually untreatable. The increasing incidences of MDR- and XDR-TB urgently call for novel drugs for TB therapy.

[+] Read More